Jin Hee Kim

ORCID: 0000-0001-5036-3326 · 13 papers in corpus
rct 2025
AJOG global reports ·doi:10.1016/j.xagr.2025.100584

BACKGROUND: Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss of bone mi…

rct 2024
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2024.06.040

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…

2024
·doi:10.1016/j.fertnstert.2024.07.557
rct 2023
·doi:10.1097/01.aog.0000929852.03048.10

INTRODUCTION: Herein, we report updated safety results to 36 months from an ongoing phase 3, 48-month study evaluating the long-term safety of elagolix (ELA) with add-back (AB) for endometriosis-associated pain (EAP) (NCT03213457). METHODS:…

2023
·doi:10.1016/j.fertnstert.2023.08.206
other 2023
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-022-01033-7

The purpose of this study was to assess the feasibility of use of a novel uterine fibroid treatment device hypothesized to cause fibroid infarction by increasing intra-tumoral pressure. Between August 2019 and January 2020, 21 uterine fibro…

rct 2022
·doi:10.1097/01.aog.0000826672.69977.4c

INTRODUCTION: Elagolix is an oral GnRH antagonist approved for the treatment of moderate to severe endometriosis-associated pain (EAP) in the US, Canada, and Israel. Hormonal add-back therapy (1 mg estradiol/0.5 mg norethindrone acetate QD)…

other 2021
F&S reports ·doi:10.1016/j.xfre.2021.05.004

OBJECTIVE: To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing heavy menstrual bleeding in women with uterine fibroids. DESIG…

rct 2020
·doi:10.1097/01.aog.0000663140.66314.38

INTRODUCTION: Evaluate the efficacy of elagolix with add-back therapy on menstrual blood loss (MBL) and safety in women with uterine fibroids (UF), heavy menstrual bleeding (HMB) and adenomyosis. METHODS: Pooled data from two investigationa…

2020
·doi:10.1002/ijgo.13276

Abstract Background COVID‐19 has impacted delivery of outpatient gynecology and shifted care toward use of telemedicine. Objective To rapidly review literature and society guidelines and create expert consensus to provide guidance regarding…

review 2018
Seminars in reproductive medicine ·doi:10.1055/s-0038-1676103

Endometriosis is a nonmalignant gynecologic disorder that can have a significant impact on a woman's quality of life with pelvic pain and possible lasting effects on one's fertility. Symptoms, when present, can be severe and affect many org…

review 2016
Current opinion in obstetrics & gynecology ·doi:10.1097/GCO.0000000000000293

PURPOSE OF REVIEW: The purpose of this article is to review the literature and discuss the advantages of robotics in benign gynecologic surgery. RECENT FINDINGS: Minimally invasive surgery has become the preferred route over abdominal surg…

case-report 2007

Xanthogranulomatous inflammation is an uncommon form of chronic granulomatous inflammation that is characterized by the presence of lipid-filled histiocytes with lymphocytes, plasma cells and neutrophils. It is best known to occur in the ki…